<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03394924</url>
  </required_header>
  <id_info>
    <org_study_id>EDP 305-201</org_study_id>
    <nct_id>NCT03394924</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Primary Biliary Cholangitis</brief_title>
  <official_title>A Phase 2 Dose Ranging, Randomized, Double Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Primary Biliary Cholangitis (PBC) With or Without an Inadequate Response to Ursodeoxycholic Acid (UDCA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Enanta Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pharmaceutical Research Associates</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Triangle Biostatistics</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Enanta Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized, double-blind study to assess the safety, tolerability, PK and efficacy of
      EDP-305 in subjects with primary biliary cholangitis
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 27, 2017</start_date>
  <completion_date type="Anticipated">April 2019</completion_date>
  <primary_completion_date type="Anticipated">March 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of subjects with at least 20% reduction in ALP from pre-treatment value or normalization of ALP at Week 12</measure>
    <time_frame>Measurement at Week 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety as measured by • Frequency of adverse events (AEs), serious AEs, and AEs leading to discontinuation through Week 12</measure>
    <time_frame>Up to 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Bilirubin</measure>
    <time_frame>Measurement at Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Alanine aminotransferase (ALT)</measure>
    <time_frame>Measurement at Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Aspartate aminotransferase (AST)</measure>
    <time_frame>Measurement at Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Gamma-Glutamyl transferase (GGT)</measure>
    <time_frame>Measurement at Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline of Enhanced Liver Fibrosis [ELF] panel</measure>
    <time_frame>Measurement at Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline of PRO C3</measure>
    <time_frame>Measurement at Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline of AST to Platelet Ratio Index [APRI]</measure>
    <time_frame>Measurement at Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline of fibrosis-4 [FIB-4])</measure>
    <time_frame>Measurement at Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Triglycerides (TG)</measure>
    <time_frame>Measurement at Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Total Cholesterol (TC)</measure>
    <time_frame>Measurement at Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in High Density Lipoprotein Cholesterol (HDL-C)</measure>
    <time_frame>Measurement at Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Low Density Lipoprotein Cholesterol (LDL-C)</measure>
    <time_frame>Measurement at Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in 5D-itch scale</measure>
    <time_frame>Measurement at Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Visual Analog Score (VAS)</measure>
    <time_frame>Measurement at Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in PBC-40 Quality of Life (QoL)</measure>
    <time_frame>Measurement at Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax of EDP-305</measure>
    <time_frame>Up to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax of EDP-305</measure>
    <time_frame>Up to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC of EDP-305</measure>
    <time_frame>Up to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of FGF19</measure>
    <time_frame>Up to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of C4</measure>
    <time_frame>Up to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of Total Bile Acids</measure>
    <time_frame>Up to Week 12</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">119</enrollment>
  <condition>Primary Biliary Cholangitis</condition>
  <arm_group>
    <arm_group_label>EDP-305 Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will take 2 tablets once a day orally for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EDP-305 Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will take 2 tablets once a day orally for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will take two tablets once a day orally for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EDP-305 Dose 1</intervention_name>
    <description>Two tablets daily for 12 weeks</description>
    <arm_group_label>EDP-305 Dose 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EDP-305 Dose 2</intervention_name>
    <description>Two tablets daily for 12 weeks</description>
    <arm_group_label>EDP-305 Dose 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Two tablets daily for 12 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  An informed consent document signed and dated by the subject.

          -  Male and female subjects of any ethnic origin between the ages of 18 and 75 years,
             inclusive

          -  Male or female with a diagnosis of PBC by at least two of the following criteria:

               -  History of ALP above ULN for at least six months

               -  Positive Anti-Mitochondrial Antibodies (AMA) titers (&gt;1/40 on immunofluorescence
                  or M2 positive by enzyme linked immunosorbent assay (ELISA) or positive
                  PBC-specific antinuclear antibodies)

          -  For subjects with no documented liver biopsy performed within 2 years, subjects must
             undergo a transient elastography (Fibroscan) showing liver stiffness &lt; 12.5 kPA

          -  Must be on a stable dose of UDCA12-20 mg/kg/day for at least 6 months prior to
             Screening or intolerant of UDCA in the opinion of the Investigator (no UDCA for at
             least 12 weeks prior to Screening)

          -  Alkaline Phosphatase (ALP) ≥ 1.67 × ULN and/or total bilirubin &gt;ULN but &lt; 2×ULN

          -  Subjects must have Screening laboratory values for Hepatitis B surface antigen
             (HBsAg), Hepatitis C surface antigen (HCsAg) and Human Immunodeficiency Virus (HIV) 1
             and 2 antibodies (Ab) as seronegative. Note: subjects previously infected by chronic
             hepatitis C and treated with direct acting antivirals (DAAs) with sustained virologic
             response (SVR) for at least 3 years will be allowed.

          -  Female subjects of childbearing potential must agree to use two effective methods of
             contraception from the date of Screening until 90 days after the last dose of EDP-305.

          -  All male participants who have not had a vasectomy must use effective contraception
             from Day -1 to 90 days after their last dose of study drug.

          -  Male subjects must agree to refrain from sperm donation from the date of Screening
             until 90 days after their last dose of study drug

          -  Screening body mass index (BMI) of 18 to 30 kg/m2 with a minimum body weight of 50 kg

          -  Subject must be willing and able to adhere to the assessments, visit schedule,
             prohibitions and restrictions, as described in this protocol

        Exclusion Criteria:

          -  Laboratory Screening Results:

               -  AST &gt;5 ULN

               -  ALT &gt;5 ULN

               -  Total bilirubin &gt;1.8 mg/dL: NOTE: Patients with Gilbert's syndrome will not be
                  allowed due to interpretability of bilirubin levels

               -  Total white blood cells (WBC) &lt;3000 cells/mm3

               -  Absolute neutrophil count (ANC) &lt;1500 cells/mm3

               -  Platelet count &lt;140,000/mm3

               -  Prothrombin time (international normalized ratio, INR) &gt;1.2

               -  Creatine kinase above upper limit of normal (ULN) except when in relation with
                  intense exercise

               -  Serum creatinine &gt;2 mg/dL or creatinine clearance &lt;60 mL/min (based on
                  Cockroft-Gault Method)

          -  Body mass index (BMI) &gt;30 or suspected to have relevant nonalcoholic fatty liver
             disease (NAFLD) as based on the judgment of the Investigator at Screening

          -  Use of colchicine, methotrexate, azathioprine, or systemic steroids in the two months
             preceding screening

          -  Current use of fibrates, including fenofibrates and statins (eg, simvastatin). Note:
             Subjects who discontinued fibrates for at least 3 months before screening can
             participate

          -  Use of an experimental treatment for PBC within the past 12 months

          -  Co-existing liver or biliary diseases, such as primary sclerosing cholangitis,
             choledocholithiasis, acute or chronic hepatitis, autoimmune hepatitis, alcoholic liver
             disease, nonalcoholic steatohepatitis (NASH), acute infection of bile duct system or
             gall bladder, history of gastrointestinal bleeding (secondary to portal hypertension),
             cirrhosis, cholangiocarcinoma diagnosed or suspected liver cancers

          -  Cirrhosis with or without complications, including history or presence of: spontaneous
             bacterial peritonitis, hepatocellular carcinoma, bilirubin &gt; 2x ULN

          -  Hepatorenal syndrome (type I or II) or Screening serum creatinine &gt; 2 mg/dL (178
             μmol/L)

          -  Prior variceal hemorrhage, uncontrolled encephalopathy, Child-Pugh Class A, B and C,
             esophageal varices, or refractory ascites within the previous 6 months of Screening
             (defined as date informed consent signed)

          -  Medical conditions that may cause nonhepatic increases in ALP (e.g., Paget's disease)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Nathalie Adda</last_name>
    <phone>617 607 0705</phone>
    <email>nadda@enanta.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Inland Empire Liver Foundation</name>
      <address>
        <city>Rialto</city>
        <state>California</state>
        <zip>92377</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zeid Kayali, MD</last_name>
    </contact>
    <investigator>
      <last_name>Zeid Kayali, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>American Research Corporation at the Texas Liver Institute</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric J Lawitz, MD</last_name>
      <phone>210-253-3426</phone>
    </contact>
    <investigator>
      <last_name>Eric Lawitz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 23, 2017</study_first_submitted>
  <study_first_submitted_qc>January 3, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 9, 2018</study_first_posted>
  <last_update_submitted>March 19, 2018</last_update_submitted>
  <last_update_submitted_qc>March 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PBC</keyword>
  <keyword>Primary Ciliary Cholangitis (PBC)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholangitis</mesh_term>
    <mesh_term>Liver Cirrhosis, Biliary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ursodeoxycholic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

